CCRN Earnings

CCRN reported its earnings on 2026-03-04, showcasing a revenue of 236.76M against an estimate of 252.25M, resulting in a -6.14% surprise. The EPS was -0.06, surpassing the expected 0.03 by -300%. The stock experienced a 8.32% price change on the earnings day and a 7.89% change over the next five days, reflecting market reactions to the results.

Following CCRN's earnings announcement on 2026-03-04, the stock price moved by 8.32% on the day of the release. Over the subsequent five days, it saw a 7.89% change. Historically, CCRN's stock price tends to shift by an average of 0.48% in the 10 days leading up to earnings and -6.74% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate CCRN's annual revenue to reach 256.69M, while the EPS is projected at 0.01. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between CCRN's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, CCRN's stock price typically moves by 0.48% in the 10 days before its earnings and -6.74% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of 0.01 and revenue of 256.69M.

The earnings call reveals a mixed financial performance with some declines in specific areas, but overall positive developments such as strong cash position, strategic investments, and optimistic guidance for future growth. The Q&A section shows confidence in achieving ambitious revenue and margin targets, strategic focus on technology and acquisitions, and market stabilization. Although there are some declines in physician staffing and unclear responses regarding federal funding, the positive aspects outweigh the negatives, suggesting a likely positive stock price movement.